Company / Cost of Revenue
AGIOS PHARMACEUTICALS, INC. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.3M
FY2025
5-year range
$0 / $6.3M
FY2021-FY2025
Trend
+52.3%
vs FY2024
Sector context
#73 of 85
Health Care
What the data says
AGIOS PHARMACEUTICALS, INC.'s cost of revenue of $6M is lower than 86% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 3 consecutive years, from $0 in FY2022 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +35.3%.
Increased from $3M to $6M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +35.3%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 85This company $6.3M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +35.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 52.3% year-over-year.
- Ranks #73 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.3M | +52.3% |
| FY2024 | $4.2M | +44.6% |
| FY2023 | $2.9M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $1.4M | +6.1% |
| FY2019 | $1.3M | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026